title: Brucella lipopolysaccharides induce cyclooxygenase-2 expression in monocytic cells.
abstract: Human brucellosis is characterized by the presence of both acute inflammatory episodes and chronic inflammation with granuloma formation. On this basis, the proinflammatory effects of smooth lipopolysaccharide of Brucella (S-LPS) were addressed and compared to those of LPS from Escherichia coli. For this purpose, the induction of cyclooxygenase-2 (COX-2), the production of the chemokine monocyte chemoattractant protein-1 (MCP-1), and the activation of the nuclear factor kappa B (NF-kappa B) were studied. S-LPS was found to induce both COX-2 expression and MCP-1 production; however, the potency of E. coli LPS exceeded that of Brucella S-LPS by some orders of magnitude. However, at concentrations above 1 microg/ml, all of the LPS produced comparable effects, including their ability to activate the NF-kappa B system. These observations help explain the inflammatory events associated with Brucella infection and the ability of Brucella to produce monocyte recruitment and granuloma formation.
authors.affiliation: Departamento de Microbiología, Facultad de Medicina, Instituo de Biología y Genética Molecular, CSIC, Valladolid, Spain.
authors.forename: L
authors.initials: L
authors.lastname: López-Urrutia
authors.forename: A
authors.initials: A
authors.lastname: Alonso
authors.forename: Y
authors.initials: Y
authors.lastname: Bayón
authors.forename: M L
authors.initials: ML
authors.lastname: Nieto
authors.forename: A
authors.initials: A
authors.lastname: Orduña
authors.forename: M
authors.initials: M
authors.lastname: Sánchez Crespo
mesh_terms: D016718:Arachidonic Acid / Q000378:metabolism; D015153:Blotting, Western; D002002:Brucella / Q000378:metabolism; D002003:Brucella abortus / Q000378:metabolism*; D017347:Brucella melitensis / Q000378:metabolism*; D002006:Brucellosis / Q000378:metabolism; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000378:metabolism; D051546:Cyclooxygenase 2; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D004926:Escherichia coli / Q000378:metabolism; D006099:Granuloma / Q000378:metabolism; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D007527:Isoenzymes / Q000096:biosynthesis*; D007962:Leukocytes / Q000378:metabolism; D008070:Lipopolysaccharides / Q000378:metabolism*; D008565:Membrane Proteins; D009000:Monocytes / Q000201:enzymology* / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis*; D013997:Time Factors
chemical_list: D018932:Chemokine CCL2; D020672:I-kappa B Proteins; D007527:Isoenzymes; D008070:Lipopolysaccharides; D008565:Membrane Proteins; D016328:NF-kappa B; D016718:Arachidonic Acid; D009569:Nitric Oxide; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases